Radiofrequency ablation in the treatment of cartilaginous lesions in the long bones: results of a pilot study.
|
| Abstract |
Atypical cartilaginous tumours are usually treated by curettage. The purpose of this study was to show that radiofrequency ablation was an effective alternative treatment. We enrolled 20 patients (two male, 18 female, mean age 56 years (36 to 72) in a proof-of-principle study. After inclusion, biopsy and radiofrequency ablation were performed, followed three months later by curettage and adjuvant phenolisation. The primary endpoint was the proportional necrosis in the retrieved material. Secondary endpoints were correlation with the findings on gadolinium enhanced MRI, functional outcome and complications. Our results show that 95% to 100% necrosis was obtained in 14 of the 20 patients. MRI had a 91% sensitivity and 67% specificity for detecting residual tumour after curettage. The mean functional outcome (MSTS) score six weeks after radiofrequency ablation was 27.1 (23 to 30) compared with 18.1 (12 to 25) after curettage (p < 0.001). No complications occurred after ablation, while two patients developed a pathological fracture after curettage. We have shown that radiofrequency ablation is capable of completely eradicating cartilaginous tumour cells in selective cases. MRI has a 91% sensitivity for detecting any residual tumour. Radiofrequency ablation can be performed on an outpatient basis allowing a rapid return to normal activities. If it can be made more effective, it has the potential to provide better local control, while improving functional outcome.
|
|---|---|
| Authors | E F Dierselhuis, P J M van den Eerden, H J Hoekstra, S K Bulstra, A J H Suurmeijer, P C Jutte |
| Journal | The bone & joint journal (Bone Joint J) Vol. 96-B Issue 11 Pg. 1540-5 (Nov 2014) ISSN: 2049-4408 [Electronic] England |
| PMID | 25371471 (Publication Type: Journal Article) |
| Copyright | ©2014 The British Editorial Society of Bone & Joint Surgery. |
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!